PharmiWeb.com - Global Pharma News & Resources
23-Jan-2019

Worldwide Market Opportunities for Hemoglobinopathies Treatment, 2019-2023 - ResearchAndMarkets.com

The "Global Hemoglobinopathies Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The hemoglobinopathies treatment market will register a CAGR of almost 11% by 2023.

Development of gene therapy to drive growth in the market

The advances of regenerative medicines in the clinical phases are expected to fuel growth of the global hemoglobinopathies treatment market.

Strong pipeline and expected approvals of late-stage molecule

The market is witnessing an acute lack of approved therapies, these late-stage pipeline molecules are expected to gain momentum during the forecast period, which will fuel the market growth.

Product recalls and tedious drug approval process

The strict regulations for providing the marketing approval for therapeutics that are being developed for the treatment of hemoglobinopathies is likely to pose a threat to the market.

Key Players

  • ApoPharma
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Medunik USA
  • Novartis

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY TYPE

  • Comparison by type
  • Sickle cell disease - Market size and forecast 2018-2023
  • Thalassemia - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: VENDOR LANDSCAPE

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ApoPharma
  • Bristol-Myers Squibb
  • Emmaus Medical
  • Medunik USA
  • Novartis

For more information about this report visit https://www.researchandmarkets.com/research/r76lgr/worldwide_market?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190123005549/en/

Editor Details

Last Updated: 23-Jan-2019